HELANA ZAKHER: Open Payments
NPI 1003527532 · VALPARAISO, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$783 in 42 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $783
Food & beverage: $783
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $239 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $136 |
| Ardelyx, Inc. | 5 | $96 |
| Madrigal Pharmaceuticals | 4 | $68 |
| QOL Medical, LLC | 3 | $59 |
| Aimmune Therapeutics, Inc. | 3 | $52 |
| Gilead Sciences, Inc. | 2 | $43 |
| Janssen Biotech, Inc. | 2 | $35 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| EVOKE PHARMA, INC. | 1 | $17 |
Products named: ENTYVIO, LINZESS, RINVOQ, IBSRELA, REZDIFFRA, Sucraid, ZENPEP, CREON.
Industry payments across IN — which companies pay providers there.
